-
aripiprazole
- atypical antipsychotics
- MOA: 5HT1A partial agonist, 5HT2A antagonist, D2 partial agonist
- USES: acute mania, maintenance of recurrant mania, approved to tx irritability in autism children 6-17
- AE: akathisia, lowest risk for diabetes
-
asenapine
- atypical antipsychotic
- MOA: 5HT2A antagonist, D2 antagoinst
- USES: schizophrenia, acute mania, and maintenance for recurrant mania
- AE: high doses can produce EPS
- subligual tablet
-
risperidone
- atypical antipsychotic
- MOA: antagonist at 5HT2A and D2
- USES: schizophrenia, acute mania, maintenance for recurrance of mania, approved for ages 13-17
- AE: at high doses can cause EPS, hyperprolactinemia, weight gain
-
olanzepine
- biopolar disorder
- MOA: blocks D2 receptors, blocks 5HT receptors - enhances DA in motor areas
- USES: acute mania, maintenance for the recurranxe of mania
- AE: highest risk for DM and dyslipidemia, dizziness, sedation, dry mouth, worst for weight gain
-
quetiapine
- bipolar disorder
- MOA: blocks D2 receptors, blocks 5HT receptors - releases DA in motor brain regions and could reduce glutamate hyperactivity
- USES: maintenance for recurrant mania, bipolar depression, acute mania, preferred for psychosis in PD and lewy body dementia
- AE: sedation, orthostatic HTN, weight gain (track throughout)
|
|
